The recent international survey of the most common methods utilized for the evaluation of the MGMT promoter methylation status, the most valuable prognostic factor of glioma, emphasized the MSP as the first method of choice among diagnostics laboratories due to its good simplicity, reproducibility, cost-effectiveness, and best correlation with clinical outcome [25]. The gene discussed is MGMT; the disease is central nervous system cancer.